Eli Lilly tests antibody drug to halt COVID-19 spread in U.S. nursing homes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Regeneron (REGN) Tops Q2 EPS by $1.18, Revenues Beat
August 5, 2020 6:39 AM EDTRegeneron (NASDAQ: REGN) reported Q2 EPS of $7.16, $1.18 better than the analyst estimate of $5.98. Revenue for the quarter came in at $1.95 billion versus the consensus estimate of $1.74 billion.
Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019(4)
Second quarter 2020 EYLEA® U.S. net sales were $1.11 billion
Second quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, were $945 million
